ETV4 overexpression in the prostate is observed in only a relatively small subset of prostate cancer patients (about 1–5%) [2–4, 29, 50]; however, since prostate cancer is common, these results are potentially relevant for a significant number of patients. Here, ETV4 is linked to prostate cancer.